Skip to main content
. 2014 Jul 1;124(8):3590–3600. doi: 10.1172/JCI75386

Figure 7. FXIII-deficient human clots retain fewer rbc after clot retraction, and FXIII inhibition prevents rbc retention in clots.

Figure 7

(A) Serum rbc content following tissue factor–initiated clot retraction of human FXIII-deficient patient plasma reconstituted with washed platelets and washed rbc from normal donors and treated with increasing doses of FXIII (0–1 U/ml, n = 6). Data represent mean ± SEM. *P < 0.02 versus FXIII-deficient plasma with no additional FXIII by ANOVA. (B) Serum rbc content following tissue factor–initiated clot retraction of normal human whole blood in the presence of the irreversible FXIIIa inhibitor, T101 (0.1–5 μM, n = 7). Data represent normalized mean ± SEM. *P < 0.02 versus absence of T101 by ANOVA.